Dianthus Therapeutics targets severe autoimmune diseases with DNTH103. Read more on DNTH's promise amid competitive ...

Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell ...

However, increasing studies suggest that activation of the complement system, via the alternative pathway, plays a crucial role in the development of AAV. In the mouse model of AAV, complement ...

This review aims to discuss recent and previous findings on the role of complement in AChR-Ab+ MG pathology, including its interaction with pathogenic antibodies and mechanisms beyond the classical ...

Eculizumab and ravulizumab are monoclonal antibodies that block the activity of the complement system’s terminal pathway. The terminal pathway is the last step of the complement pathway that ...

TIME speaks with the winner of the XPrize Carbon Removal award, Mati Carbon, which was announced at the TIME100 Summit.

The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with tanruprubart at a dose of 30 mg/kg recovered to a healthy state with a score of 0 or ...

Zhang said this Character drug addresses a different node in the complement pathway. Based on insight from the observational study, Zhang said Character found this node has stronger genetic ...

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway. More than 6000 rare diseases—those ...

Showing Rapid and Durable Benefit Across Clinical Measures and Time Points Educational Symposium Focuses on Advancing GBS Care and Role of Classical Complement Pathway New Disease Education ...

Gómez-Sifontes, A. , Diaz-Tablero, J. and Rodriguez, Y. (2025) Anti-C1q Antibodies as Markers of Renal Involvement in Patients with Systemic Lupus Erythematosus, Bolivar City, Venezuela. Open Access ...